Tirilazad for acute ischaemic stroke

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 10, 2001, Pages

 

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008531598     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002087     Document Type: Review

References (63)

1. Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. A pilot randomized, vehicle controlled, double blind European safety study of high dose tirilazad mesylate in patients with acute ischemic stroke (protocol M/2700/0057). Kalamazoo, Pharmacia & Upjohn 1996, pp 1-40.
2. Ford G, Haley EC, Hwang LJ, for the RANTTAS Investigators. Correlations between outcome measures in an ischemic stroke trial. Stroke 1995;26(1):158 (abstract).
3. Johnston KC, Connors AF, Wagner DP, Knaus WA, Wang X-Q, Haley EC, for the Randomized Trial of Tirilazad mesylate in Acute Stroke (RANTTAS) Investigators. A predictive risk model for outcomes of ischemic stroke. Stroke 2000;31:448-455.
4. Johnston KC, Knaus WA, Wagner DP, Haley EC, for the RANTTAS Investigatots. A predictive model for outcomes in acute ischemic stroke. Ann Neurol 1998;44(3):513 (abstract).
5. Peters GR, Eckert SM, Naberhuis-Stehouwer SA, Musch BC. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (RANTTAS) (protocol P/2700/0035). Kalamazoo, Pharmacia & Upjohn 1996, pp 1-54.
6. Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, for the RANTTAS Invetsigators. Infarct volume as a surrogate or auxiliary measure in ischemic stroke clinical trials. Stroke 1999;30:293-298.
7. The RANTTAS Investigators. A randomised trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-8.
8. The RANTTAS Investigators. Randomized trial of tirilazad in acute stroke (RANTTAS). Stroke 1996;27:195 (Abstract).
9. Haley EC. High-dose tirilazad for acute stroke (RANTTAS II). Stroke 1998;29:1256-7.
10. Musch BC, Fleishaker DL, Naberhuis-Stehouwer SA, Peters GR. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of high dose tirilazad mesylate in patients with acute ischemic stroke (RANTTAS II) (protocol M/2700/0081). Kalamazoo, Pharmacia & Upjohn 1997, pp 1-56.
11. Haley EC, Sheppard G, Burch G, Putman S, Adams R, Peters G, Hansen C, Torner J. Safety study of tirilazad mesylate in acute stroke (STIPAS). Neurology 1994;43:A263 (Abstract).
12. Peters GR, Naberhuis-Stehouwer SA, Bryan WJ. A phase II dose escalation study of the safety and tolerance of tirilazad mesylate (U-74006F) in patients with acute ischemic stroke (protocol P/2700/0020). Kalamazoo, The Upjohn Company 1993, pp 1-55.
13. The STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25:418-23.
14. Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. An international, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS) (protocol P/2700/0037). Kalamazoo, Pharmacia & Upjohn 1996, pp 1-52.
15. Peters GR, Hwang L-J, Musch B, Brosse DM, Orgogozo JM. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in acute ischemic stroke (TESS study). Stroke 1996;27:195 (Abstract).
16. van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo J-M, Ringelstein EB, Bath PMW, van Gijn J. No effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke. Cerebrovasc Dis 2000;10 (suppl 2):107 (abstract).
17. Musch BC, Naberhuis-Stehouwer SA, Brosse D, Peters GR. An international, randomized, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS II) (protocol M/2700/0088). Kalamazoo, Pharmacia & Upjohn 1997, pp 1-56.
18. van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo J-M, Ringelstein EB, Bath PMW, van Gijn J. No effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke. Cerebrovasc Dis 2000;10 (suppl 2):107 (abstract).
19. Anderson DK, Braughler JM, Hall EK, Waters TR, McCall JM, Means ED. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 1988;69:562-567.
20. Bath FJ, Owen VE, Bath PMW. Quality of full and final publications reporting acute stroke trials. A systematic review. Stroke 1998;29:2203-2210.
21. Bath PM. Tirilazad in acute ischaemic stroke: a systematic review. Cerebrovasc Dis 1998;8(suppl 4):34 (Abstract).
22. Bath P, Bath F. Prostacyclin and analogues in acute ischaemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD000177. DOI: 10.1002/14651858.CD000177]
23. Bath PMW, Bath FJ, Asplund K. Pentoxifylline, propentofylline and pentifylline in acute ischaemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD000162. DOI: 10.1002/14651858.CD000162]
24. Beck T, Bielenberg GW. Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat. Brain Research 1990;532:336-338.
25. Burrin JM, Hart GR. Effects of a novel 21-amino stroid, U74006F, on the rat pituitary-adrenocortical axis. Journal of Endocrinology 1990;126:203-209.
26. Clarke HE, Kassell NFMD, Apperson-Hansen CM, Maile MHMS, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997;86:466-475.
27. Davis SM, Albers GW, Diener H-C, Lees KR, Norris J (ASSIST Steering Committee). Termination of acute stroke studies involving selfotel treatment. Lancet 1997;349:32.
28. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J, for the ASSIST Investigators. Selfotel in acute ischemic stroke. Possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-54.
29. del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1 Drugs promoting cerebral blood flow. J Int Med 1995;237:79-88.
30. The Enlimomab Acute Stroke Trial Investigators. The Enlimomab acute stroke trial: final results. Cerebrovasc Dis 1997;7(suppl 4):18 (Abstract).
31. Fleishaker JC, Peters GR, Cathcart BS. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, 1 21-aminosteroid free radical scavenger. I. Single-dose administration. J Clin Pharmacol 1993;33:175-181.
32. Fleishaker JC, Peters GR, Cathcart BS. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J Clin Pharmacol 1993;33:182-190.
33. Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Int J Clin Pharmacol Therapeutics 1997;35:28-32.
34. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized trial. J Am Med Assoc 1999;282:2003-11.
35. Goldstein LB, Brott TG, Kothari RU, Smith WS. Clinical stroke trials. Guarding against bias. Stroke 1999;30:1165-6.
36. Grotta J. Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy. J Int Med 1995;237:89-94.
37. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2001, Issue 1. [Art. No.: CD000029. DOI: 10.1002/14651858.CD000029]
38. Hall ED, Yonkers PA, McCall JM, Braughler JM. Effects of the 21-aminosteroid U74006F on experimental head injury in mice. J Neurosurg 1988;68:456-461.
39. Hall D, Kay E, Pazara E, Braughler JM. 21-Aminosteroid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils. Stroke 1988;19, 8:997-1003.
40. Hall E D, Smith SL. The 21-aminosteroid antioxidant tirilazad mesylate, U-74006F, blocks cortical hypoperfusion following spreading depression. Brain Research 1991;553:243-248.
41. Horn J, Limburg L, Orgogozo JM. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD001928. DOI: 10.1002/14651858.CD001928]
42. Jennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet 1975;i:480-484.
43. Kassell NF, Clarke HE Jr, Apperson-Hansen C, Alves WM. Randomised, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;8:220-229.
44. Lanzino G, Kassell NF, Dorsch NWC, Pasqualin A, Brandt L, Schmiedek P, Truskowski LL, Alves WM. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part 1. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999;90:1011-1017.
45. Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999;90:1018-1024 1999;90:1018-1024.
46. Lesiuk H, Sutherland G, Peeling J, Butler K, Saunders J. Effect of U74006F on forebrain ischemia in rats. Stroke 1991;22:896-901.
47. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Maryland State Med J 1965;14:61-65.
48. Marshall LF, Maas AI, Marshall SB, Bricolo A, Fearnside M, Iannotti F, Klauber MR, Lagarrigue J, Lobato R, Persson L, Pickard JD, Piek J, Servadei F, Wellis GN, Morris GF, Means ED, Musch B. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 1998;89:519-525.
49. Meden P, Overgaard K, Pedersen H, Boysen G. Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 1996;6:141-148.
50. Mohiuddin AA, Bath FJ, Bath PMW. Theophylline, aminophylline, caffeine and analogues, in acute ischaemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD000211. DOI: 10.1002/14651858.CD000211]
51. Olsen KS, Videbaek C, Agerlin N, Kroll M, Boge-Rasmussen T, Paulson O, Gjerris F. The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers. Anesthesiology 1993;79,4:666-671.
52. Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids following acute presumed ischaemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD000064. DOI: 10.1002/14651858.CD000064]
53. Reith J, Jorgensen S, Pedersen P, Nakayama H, Raaschou H, Jeppesen L, Olsen T. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996;347:422-5.
54. Sacchetti ML, Toni D, Fiorelli M, Argentino C, Fieschi C. The concept of combination therapy in acute ischemic stroke. Neurology 1997;49(suppl 4):S70-4.
55. Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, for the RANTTAS Investigators. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. Stroke 1999;30:293-8.
56. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999;30:993-6.
57. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE, The STAT Participants. Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: a randomized controlled trial. J Am Med Assoc 2000;283:2395-402.
58. van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo JM, Ringelstein EB, Bath PMW, van Gijn J, TESS Investigators. The effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke. In: van der Worp editor(s). Treatment of acute ischaemic stroke with antioxidants. The gap between laboratory and clinic. Utrecht: Utrecht University PhD Thesis, 1999:83-94.
59. Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T, INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204-10.
60. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD000213. DOI: 10.1002/14651858.CD000213.]
61. Young W, Wojak J, DeCrescito V. 21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia. Stroke 1988;19, 8:1013-1019.
62. Zuccarello M, Marsch JT, Schmitt G, Woodward J, Anderson DK. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 1989;71:98-104.
63. Bath PMW, Blecic S, Bogousslavsky J, Boysen G, Davis S, Diez-Tejedor E, Ferro JM, Gommans J, Hacke W, Indredavik B, Norrving B, Orgogozo JM, Ringelstein EB, Sacchetti ML, Iddenden R, Bath FJ, Musch BC, Brosse DM, Naberhuis-Stehouwer SA. Tirilazad mesylate in acute ischaemic stroke. A systematic review. Stroke 2000;32:2257-65.